Menu

Recent Interviews

Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


Karim Nanji, CEO, Marble Financial

Karim Nanji
CEO | Marble Financial
1200-1166 Alberni Street, V6E 3Z3 Vancouver (CAN)

info@marblefinancial.ca

+1-604-336-0185

Interview with Marble Financial: Fintech innovator plans expansion into the US


04. March 2021 | 09:16 CET

NanoRepro, EXMceuticals, Deutsche Telekom - The profiteers of the new world!

  • Cannabis
Photo credits: pixabay.com

The world has changed since last year. The goal is to fight and contain the virus, which has destroyed our everyday life. In addition to the vaccine manufacturers such as BioNTech, AstraZeneca or Moderna, there are more and more new winners emerging from nowhere to become new stock market stars. Currently, the dominant topic, apart from the vaccination programs that are still hardly taking place in Germany, is the "national testing strategy." At the very least, this should enable a more regular and open life. Be there!

time to read: 3 minutes by Stefan Feulner


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


The rocket ignites

You can tell this stock market story to your grandchildren one day. It's the incredible story of NanoRepro, a Marburg-based Company that was initially in the self-diagnostics business and had 25 rapid tests in its portfolio - including an HIV test, two pregnancy tests and five others purely for medical use. In 2019, the Marburg-based Company generated annual sales of EUR 1.2 million. The Company saw its opportunity in the Corona pandemic. Already in October 2020, sales exploded due to the antigen tests offered by NanoRepro. Now the Marburg-based Company is thick in business with the Corona rapid tests. The Company recently concluded a cooperation with ViroMed.

Sustainable business?

The Hamburg-based Company buys Corona antigen rapid tests from the anterior nasal swab in a volume of around EUR 30 million from NanoRepro. In addition, NanoRepro has been added to the list of approved "antigen tests" of the German Federal Institute for Drugs and Medical Devices (BfArM). The Company could receive a further boost if approval were granted for self-testing by laymen. We assume that rapid tests will become established in our lives, at least in the near future. However, the competition here is becoming increasingly fierce. The share price, which was still below EUR 2.0 last year, has since increased tenfold and reached an all-time high of EUR 22.40, corresponding to a market capitalization of approximately EUR 1.5 billion and a stock market value of around EUR 185 million. It smells like overheating!

Revolutionary merger announced

Things could go similarly fast as with NanoRepro at medical cannabis Company EXMceuticals. While last year it was still researching a disinfectant to combat the Coronavirus under the auspices of the European Union, among others, a milestone in the history of the young Canadian Company was sealed yesterday. Originally, EXMceuticals' goal was to become a large-scale producer of high-quality cannabis ingredients for the pharmaceutical market. To this end, the Canadian-based Company has positioned itself in the European market and owns an EU-certified processing facility in Portugal to extract active ingredients from cannabis plants. Access to the European market now becomes key to the forward-looking transaction.

Big player emerges

EXMceuticals plans to merge with Global Cannabinoids, a leading US B2B distributor of hemp-derived cannabinoids and finished products in bulk and wholesale. Upon completing the merger, a top hemp and cannabinoid-based product distribution company will be created, operating under GC. The merger will create a player with an unprecedented platform to serve the rapidly growing global market of cannabinoid-based products. In 2027, the global CBD industry is expected to reach USD 123 billion in sales. In the US, Global Cannabinoid currently serves over 70,000 customers with over 1,000 units of product inventory.

Portugal's license will allow the future global player to roll out its distribution to the rapidly growing European market. A private placement of up to CAD 6.0 million is also planned. The net proceeds will be used to fund the merger, the pro forma business plan and general corporate purposes. The CBD market is still in the early stages of growth, particularly in Europe. The merger should enable GC to gain market share globally. EXMceuticals is listed in Frankfurt and was traded at EUR 0.135 before it got halted and has a market capitalization of just under EUR 8.0 million. A very interesting growth story is emerging here!

Do it again...and better!

Deutsche Telekom dares once again to control Corona through technology. After the somewhat subdued success in developing the Corona warning app together with the software provider SAP, which has been downloaded 26 million times and the benefits are not yet fully known, the Bonn-based Company wants to develop the long-awaited vaccination certificate for Germany. According to the Company's headquarters, a proposal has been sent to the German Federal Ministry of Health. The vaccination passport is to pursue the goal that travel can be revived in the Corona Crisis.

The Ministry of Health's goal is to have a finished vaccination passport available before the summer vacation. The software giant SAP did not throw its hat into the ring this time. This time, a shareholding by the US group Microsoft might be a possibility. The Deutsche Telekom share continued its upward trend, which began in March 2020, and yesterday traded at EUR 10.58, up 0.90%. The next resistance is at EUR 11.0. Should these be broken through, the next price target would be EUR 13.0.


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

07. December 2020 | 10:01 CET | by André Will-Laudien

EXMceuticals, Aurora, Xphyto Therapeutics - Cannabis 2.0 and Psilocybin!

  • Cannabis

The North American Cannabis Index has brought itself back to life in October! The index lost 80% since the beginning of 2019, but it's going up again with the survivors of the industry. Overall, the capitalization of the sector has decreased by 85%, with the election of Joe Biden, the second buying wave of purchases is underway. If hemp production was the initial focus, it is now the applications, the achieved market access and new active ingredient combinations. In the slipstream of the therapeutic plant customer, another topic came to the fore that has caused investors' hearts to stutter in recent weeks: the psychedelic drugs in the form of psilocybin. Psilocybin has been used as an entheogen and hallucinogenic drug since prehistoric times. Now the medical applications are being investigated. The trend is already running at full speed, the Canadian brokerage house Canaccord estimates the market volume of all indications that are suitable for treatment with active psychedelic ingredients to be USD 100 billion.

Read

15. July 2020 | 12:23 CET | by Mario Hose

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

  • Cannabis

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.

Read

19. May 2020 | 15:02 CET | by Mario Hose

Aphria, Aurora Cannabis, Canopy Growth, EXMceuticals - do not miss the entry!

  • Cannabis

The nationwide and anonymous advertising format of Deutsche Post is called POSTAKTUELL and is published regularly in large print runs. The stack of advertising is wrapped in a foil and the practical added value for the recipient is the TV guide. The front of POSTAKTUELL is particularly eye-catching and anyone who advertises there will reach a lot of people. In the meantime, advertising for products and applications with active ingredients from the cannabis plant is already being done there. CBD reaches the general public and despite the Corona Pandemic, the industry's stocks are running in turnaround mode and have left the lows.

Read